Hypomethylating Agent Maintenance for Favorable and Intermediate Risk Acute Myeloid Leukemia

被引：0
|
作者：
Singh, Reema [1 ]
Halder, Rohan [1 ]
Verma, Megha [1 ]
Mehta, Pallavi [1 ]
Agrawal, Narendra [1 ]
Ahmed, Rayaz [1 ]
Bhurani, Dinesh [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol & BMT, New Delhi, India
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-162124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：11713 / 11715
页数：3
相关论文
共 50 条
  • [21] Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
    Jamy, Omer Hassan
    Worth, Sarah
    Rangaraju, Sravanti
    Bachiashvili, Kimo
    Vachhani, Pankit
    Bhatia, Ravi
    BLOOD, 2021, 138
  • [22] Hypomethylating Agent Therapy for Chronic Myelomonocytic Leukemia Does Not Impact Acute Myeloid Leukemia Transformation or Survival
    Niyongere, Sandrine
    Kathari, Yamini
    Singh, Zeba
    Vannorsdall, Emily J.
    Emadi, Ashkan
    Vu Doung
    Baer, Maria R.
    BLOOD, 2020, 136
  • [23] Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
    Saliba, Antoine N.
    John, August J.
    Kaufmann, Scott H.
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 125 - 142
  • [24] Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
    Srivastava, Pragya
    Paluch, Benjamin E.
    Matsuzaki, Junko
    James, Smitha R.
    Collamat-Lai, Golda
    Karbach, Julia
    Nemeth, Michael J.
    Taverna, Pietro
    Karpf, Adam R.
    Griffiths, Elizabeth A.
    LEUKEMIA RESEARCH, 2014, 38 (11) : 1332 - 1341
  • [25] Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax
    Bouligny, Ian
    Murray, Graeme
    Thuy Ho
    Gor, Juhi
    Zacholski, Kyle
    Wages, Nolan
    Grant, Steven
    Maher, Keri
    BLOOD, 2023, 142
  • [26] Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML)
    Stroopinsky, Dina
    Pyzer, Athalia Rachel
    Palmer, Kristen A.
    Coll, Maxwell D.
    Bar-Natan, Michal
    Rajabi, Hasan
    Somaiya, Poorvi
    Luptakova, Katarina
    Jain, Salvia
    McMasters, Malgorzata
    Levine, James D.
    Arnason, Jon
    Taverna, Pietro
    Kufe, Donald
    Avigan, David
    Rosenblatt, Jacalyn
    BLOOD, 2014, 124 (21)
  • [27] Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes
    Kim, Kunhwa
    Ong, Faustine
    Li, Ziyi
    Shamanna, Rashmi Kanagal
    Bravo, Guillermo Montalban
    Kadia, Tapan
    Jabbour, Elias
    Pemmaraju, Naveen
    Hammond, Danielle
    Short, Nicholas
    Ravandi, Farhad
    Alvarado, Yesid
    Pierce, Sherry
    Dong, Xiao Qin
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Chien, Kelly
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S313 - S314
  • [28] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [29] Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
    Ball, Brian
    Komrokji, Rami S.
    Ades, Lionel
    Sekeres, Mikkael A.
    DeZern, Amy E.
    Pleyer, Lisa
    Vey, Norbert
    Almeida, Antonio
    Germing, Ulrich
    Cluzeau, Thomas
    Platzbecker, Uwe
    Gore, Steven D.
    Fenaux, Pierre
    Prebet, Thomas
    BLOOD ADVANCES, 2018, 2 (16) : 2063 - 2071
  • [30] Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation
    Cao, Yigeng
    Zheng, Xinhui
    Zhang, Haixiao
    Wang, Mingyang
    Guo, Wenwen
    Chen, Xin
    Zhai, Weihua
    Wei, Jialin
    Yang, Donglin
    Huang, Yong
    Pang, Aiming
    Feng, Sizhou
    Jiang, Erlie
    Han, Mingzhe
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
12345